1. Scrip
  2. >>Business
  3. >>Financing

Three IPOs, Three SPAC Mergers, But One Company Opted Out

Talaris, Valneva, Anebulo Make 43 US Biopharma IPOs In 2021

 
• By Mandy Jackson

Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.

SPAC vs IPO symbol on dollar bill background
Three companies launched IPOs grossing $264.5m, while three SPAC mergers with concurrent PIPE financings will raise up to $1.1bn • Source: Alamy

Six biopharmaceutical companies traveled down a path toward the US stock market during the first week of May, but half took the initial public offering route and the other half decided to go public by merging with a special purpose acquisition corporation (SPAC). A seventh company, Gyroscope Therapeutics plc, was driving toward an IPO earlier in the week, but on 7 May it stalled out.

London-based gene therapy firm Gyroscope would have had the largest first-time offering of the week at its proposed terms of 6.75 million American depository shares (ADSs) at $20-$22 each, but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Finance Watch: Public Company Fundraising Sank Across The Board In Q1

 
• By Mandy Jackson

Public Company Edition: Biomedtracker’s first quarter 2025 financing report shows follow-on offerings, IPOs and PIPEs fell sharply from Q1 of 2024. In recent transactions, Teva sold $2.3bn worth of notes, Regenxbio executed a royalty deal for up to $250m and Aura’s FOPO grossed $75m.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.